Department of Otolaryngology-Head and Neck Surgery, Kandong Sacred Heart Hospital, Hallym University School of Medicine, 445 Gil-Dong, Kangdong-Gu, Seoul 134-701, South Korea.
J Endocrinol Invest. 2013 Sep;36(8):584-7. doi: 10.3275/8879. Epub 2013 Feb 27.
IL22RA1 (Interleukin 22 receptor-alpha 1), a member of the class II cytokine receptor family, mediates diverse biologic activities and appears to be important in pathogen defense, wound healing, and tissue reorganization. Polymorphisms in genes encoding inflammatory cytokines are associated with increased cancer risk.
The aim of this study was to evaluate the association between the single nucleotide polymorphisms (SNP) in the IL22 and IL22RA1 and papillary thyroid cancer (PTC), and to assess the relationship between the SNP in the IL22 and IL22RA1 and the clinical parameters of PTC.
Study enrolled experimental group of 94 PTC patients and 213 controls. PTC patients were grouped and compared for clinical PTC parameters. One promoter SNP of IL22, -429C/T (rs2227485), and one SNP of IL22RA1, Arg518Gly (rs3795299) were analyzed using direct sequencing. Genetic data were analyzed using Helixtree, SNPAnalyzer Pro, SNPStats, and Haploview.
A SNP in IL22 (rs2227485) was significantly associated with PTC (codominant2 model [C/C vs T/T], odds ratio (OR) 2.39, 95% confidence interval (CI) 1.21-4.71, p=0.012; dominant model, OR 1.89, 95% CI 1.08-3.31, p=0.022). The allele T frequency of rs2227485 in IL22 was also associated with PTC (OR 1.59, 95% CI 1.13-2.25, p=0.009). According to clinical parameters, rs2227485 of IL22 was associated with number of cancers (dominant model, OR 3.03, 95% CI 1.02-9.01, p=0.035). By haplotype analysis, TG was associated with PTC (codominant model, OR 1.52, 95% CI 1.07-2.16, p=0.019; dominant model, OR 1.91, 95% CI 1.13- 3.24, p=0.015). Genotype and allele analysis of rs3795299 in IL22RA1 showed no significant differences between PTC patients and controls.
The rs2227485 SNP in IL22 might be associated with the risk and the multifocality of PTC.
IL22RA1（白细胞介素 22 受体-α 1）是细胞因子受体家族 II 类的成员，介导多种生物学活性，似乎在病原体防御、伤口愈合和组织重排中很重要。编码炎症细胞因子的基因多态性与癌症风险增加有关。
本研究旨在评估 IL22 和 IL22RA1 单核苷酸多态性（SNP）与甲状腺乳头状癌（PTC）之间的关联，并评估 IL22 和 IL22RA1 中的 SNP 与 PTC 的临床参数之间的关系。
本研究纳入了 94 例 PTC 患者和 213 例对照作为实验组。对 PTC 患者进行分组并比较临床 PTC 参数。使用直接测序分析 IL22 的一个启动子 SNP（-429C/T，rs2227485）和 IL22RA1 的一个 SNP（Arg518Gly，rs3795299）。使用 Helixtree、SNPAnalyzer Pro、SNPStats 和 Haploview 分析遗传数据。
IL22 中的 SNP（rs2227485）与 PTC 显著相关（共显性 2 模型 [C/C 与 T/T]，比值比（OR）2.39，95%置信区间（CI）1.21-4.71，p=0.012；显性模型，OR 1.89，95%CI 1.08-3.31，p=0.022）。IL22 中 rs2227485 的等位基因 T 频率也与 PTC 相关（OR 1.59，95%CI 1.13-2.25，p=0.009）。根据临床参数，IL22 中的 rs2227485 与癌症数量有关（显性模型，OR 3.03，95%CI 1.02-9.01，p=0.035）。通过单倍型分析，TG 与 PTC 相关（共显性模型，OR 1.52，95%CI 1.07-2.16，p=0.019；显性模型，OR 1.91，95%CI 1.13-3.24，p=0.015）。IL22RA1 中 rs3795299 的基因型和等位基因分析在 PTC 患者和对照组之间没有显示出显著差异。
IL22 中的 rs2227485 SNP 可能与 PTC 的风险和多灶性有关。
